The stock of Juno Therapeutics Inc (NASDAQ:JUNO) is a huge mover today! About 1.96 million shares traded hands or 47.37% up from the average. Juno Therapeutics Inc (NASDAQ:JUNO) has declined 32.18% since April 8, 2016 and is downtrending. It has underperformed by 37.83% the S&P500.
The move comes after 6 months positive chart setup for the $3.56B company. It was reported on Nov, 10 by Barchart.com. We have $48.50 PT which if reached, will make NASDAQ:JUNO worth $2.21 billion more.
Juno Therapeutics Inc (NASDAQ:JUNO) Ratings Coverage
Out of 9 analysts covering Juno Therapeutics Inc (NASDAQ:JUNO), 7 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 78% are positive. Juno Therapeutics Inc has been the topic of 18 analyst reports since July 22, 2015 according to StockzIntelligence Inc. Barclays Capital initiated it with “Equal-Weight” rating and $48 target price in Wednesday, July 6 report. The stock of Juno Therapeutics Inc (NASDAQ:JUNO) earned “Buy” rating by Citigroup on Thursday, February 25. Goldman Sachs initiated Juno Therapeutics Inc (NASDAQ:JUNO) rating on Wednesday, November 18. Goldman Sachs has “Neutral” rating and $50 price target. The firm earned “Buy” rating on Monday, August 24 by Standpoint Research. On Friday, August 5 the stock rating was maintained by Maxim Group with “Buy”. The stock has “Neutral” rating given by JP Morgan on Friday, July 8. As per Thursday, October 29, the company rating was downgraded by Standpoint Research. FBR Capital initiated the stock with “Outperform” rating in Tuesday, August 18 report. Suntrust Robinson initiated Juno Therapeutics Inc (NASDAQ:JUNO) rating on Friday, January 29. Suntrust Robinson has “Buy” rating and $50 price target. The firm has “Outperform” rating by FBR Capital given on Friday, July 8.
According to Zacks Investment Research, “Juno Therapeutics, Inc. is a biopharmaceutical company. The Company develops cellular immunotherapies based on two platforms – Chimeric Antigen Receptors (CARs) and T Cell Receptors (TCRs) technologies. Its clinical CD19 product candidates include JCAR015 that is in Phase I clinical trials for adult patients with relapsed/refractory B cell acute lymphoblastic leukemia (r/r ALL); JCAR017, which is in Phase I/II trials for pediatric patients with r/r ALL whose cancer has recurred after a bone marrow transplant; and JCAR014 that is in Phase I/II trials to treat various B cell malignancies in patients relapsed or refractory to standard therapies. Juno Therapeutics, Inc. is headquartered in Seattle, Washington.”
Insitutional Activity: The institutional sentiment increased to 1.34 in Q2 2016. Its up 0.26, from 1.08 in 2016Q1. The ratio improved, as 25 funds sold all Juno Therapeutics Inc shares owned while 36 reduced positions. 23 funds bought stakes while 59 increased positions. They now own 44.56 million shares or 5.68% more from 42.17 million shares in 2016Q1.
Amalgamated Fincl Bank has invested 0.02% of its portfolio in Juno Therapeutics Inc (NASDAQ:JUNO). Financial Bank Of Montreal Can accumulated 38 shares or 0% of the stock. Architects holds 300 shares or 0% of its portfolio. Ubs Asset Management Americas holds 35,464 shares or 0% of its portfolio. Perceptive Limited Liability Corporation reported 1,113 shares or 0% of all its holdings. Fred Alger Mgmt Inc accumulated 35,692 shares or 0.01% of the stock. Winfield Associate Incorporated owns 20 shares or 0% of their US portfolio. Morgan Stanley last reported 0.02% of its portfolio in the stock. Jpmorgan Chase And has 0% invested in the company for 4,774 shares. Legal And General Grp Public Limited Company has 0% invested in the company for 5,470 shares. Susquehanna International Group Inc Ltd Liability Partnership last reported 0% of its portfolio in the stock. Point72 Asia (Hong Kong) accumulated 100 shares or 0% of the stock. Da Davidson & Communications holds 0.01% of its portfolio in Juno Therapeutics Inc (NASDAQ:JUNO) for 12,018 shares. Springbok Cap Management last reported 0% of its portfolio in the stock. Citigroup last reported 0% of its portfolio in the stock.
More recent Juno Therapeutics Inc (NASDAQ:JUNO) news were published by: Fool.com which released: “Better Buy: Ziopharm Oncology, Inc. vs. Juno Therapeutics” on November 03, 2016. Also Fool.com published the news titled: “Is Juno Therapeutics a Bargain or a Value Trap?” on November 07, 2016. Fool.com‘s news article titled: “Better Buy: Juno Therapeutics vs. Inovio Pharmaceuticals” with publication date: October 28, 2016 was also an interesting one.
JUNO Company Profile
Juno Therapeutics, Inc. (Juno), incorporated on August 5, 2013, is a biopharmaceutical firm focused on re-engaging the bodyâ€™s immune system to revolutionize the treatment of cancer. The Firm is developing cell cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Juno’s product candidates, JCAR015, JCAR017 and JCAR014, utilize CAR technology to target CD19, a protein expressed on the surface of various B cell leukemias and lymphomas. The Company’s CAR and TCR technologies alter T cells ex vivo, or outside the body. In addition, the Company holds license to vipadenant, a small molecule adenosine A2a (A2a) receptor antagonist that has the potential to disrupt important immunosuppressive pathways in the tumor microenvironment in certain cancers.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.